Analytical Tool - The Commercial Success of Cancer Therapeutic AntibodiesBioSeeker Group ABJune 29, 2006 SKU: BIOS1316495 |
| Executive Summary
"Analytical Tool - The Commercial Success of Cancer Therapeutic Antibodies" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in antibody R&D and business development in oncology. It is at the same time a map of the research and development, a history of the achievements up to date, and a guide pointing out the directions of the future. The product as well, lays the framework of current treatment strategies and their progress. This tool provides you with an immense amount of information structured and analyzed to assist you in your work. It is designed to assist you in finding right partners, optimizing your licensing deals, wisely choosing which projects give you the best competitive advantage, and assuring you that your decisions have been based on the most accurate, validated and precise facts available. Included in this advantageous package are two products already appreciated by many of our customers - The Commercial Success of Cancer Therapeutic Antibodies - The Formation of a Second Wave and Antibodies in Oncology: Drug Pipeline Update 2006*. The Package Includes
|
Related Markets
Oncology/Hematology Reports
- Triple Analysis: Prostate Cancer, Protein Kinase Inhibitors and Peptides
- Triple Analysis: Prostate Cancer, Protein Kinase Inhibitors and Antibodies
- Triple Analysis: Prostate Cancer, Cancer Vaccines and Protein Kinase Inhibitors
- Triple Analysis: Prostate Cancer, Apoptosis and Protein Kinase Inhibitors
- Triple Analysis: Prostate Cancer, Angiogenesis and Protein Kinase Inhibitors
